<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530344</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-308</org_study_id>
    <nct_id>NCT04530344</nct_id>
  </id_info>
  <brief_title>Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo</brief_title>
  <official_title>A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the duration of response following withdrawal of&#xD;
      ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued&#xD;
      use of ruxolitinib cream in participants who have completed either Study NCT04052425 or&#xD;
      NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream&#xD;
      BID for the previous 28 to 52 weeks depending on their initial randomization in the parent&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">January 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort A : Time to Relapse</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>Defined as the time when a participant does not achieve F-VASI75. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort A : Time to maintain ≥ F-VASI90 response</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>Defined as time to maintain ≥ 90% improvement in F-VASI Score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI50</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 50% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI75</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 75% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving F-VASI90</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 90% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI50</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 50% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI75</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 75% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving T-VASI90</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>≥ 90% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Measurement of F-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>F-VASI actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in F-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in F-VASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in F-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in F-VASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Measurement of T-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>T-VASI actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in T-VASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in T-VASI</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in T-VASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Measurement of T-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>T-BSA actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in T-BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in T-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in T-BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Measurement of F-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>F-BSA actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in F-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in F-BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in F-BSA</measure>
    <time_frame>Baseline through Week 108</time_frame>
    <description>Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in F-BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving a VNS of 4 or 5</measure>
    <time_frame>Extension period through Week 108</time_frame>
    <description>The VNS is a patient-reported measure of vitiligo treatment success, which has a 5-point scale, with 1 being more noticeable and 5 being no longer noticeable. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Cohort A : ruxolitinib cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A : Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B : roxolitinib cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ruxolitinib</intervention_name>
    <description>ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.</description>
    <arm_group_label>Cohort A : ruxolitinib cream</arm_group_label>
    <arm_group_label>Cohort B : roxolitinib cream</arm_group_label>
    <other_name>INCB018424 Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle cream is a topical formulation applied as a thin film to affected areas.</description>
    <arm_group_label>Cohort A : Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB&#xD;
             18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with&#xD;
             vitiligo.&#xD;
&#xD;
          -  Currently tolerating ruxolitinib cream in the parent study and no safety concerns per&#xD;
             investigators judgment.&#xD;
&#xD;
          -  Has demonstrated compliance, as assessed by the investigator, with the parent study&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, and any&#xD;
             other study procedures indicated in this protocol.&#xD;
&#xD;
          -  Male and female participants must be willing to take appropriate contraceptive&#xD;
             measures to avoid pregnancy or fathering a child.&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign an ICF or written informed consent of&#xD;
             the parent(s) or legal guardian and written assent from the participant when possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been permanently discontinued from study treatment in the parent study for any&#xD;
             reason.&#xD;
&#xD;
          -  Participants with an uncontrolled intercurrent illness or any concurrent condition&#xD;
             that, in the investigator's opinion, would jeopardize the safety of the participant or&#xD;
             compliance with the Protocol.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
&#xD;
          -  Participants who live with anyone participating in any current Incyte-sponsored&#xD;
             ruxolitinib cream study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cahaba Dermatology</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Desert Sky Dermatology</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Oc Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center For Dermatology Cosmetic and Laser Surgery</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marvel Clinical Research Llc</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitiligo &amp; Pigmentation Institute of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acrc Studies</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center Inc</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harmony Medical Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic Inc.</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Avita Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forcare Clinical Research Fcr Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Randall Dermatology</name>
      <address>
        <city>West Lafayette</city>
        <state>Indiana</state>
        <zip>47906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Delricht Clinical Research - Clinedge - Ppds Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical Partners</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Lakes Research Group Inc</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jdr Dermatology Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Suny Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Dermatology Specialists Greenwich</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine At Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of New York Inc</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates Llc</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kgl Skin Study Center</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Plymouth Meeting</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Tennessee Llc</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Dermatology</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Dermatology and Laser Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners Llc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Unimed Eood</name>
      <address>
        <city>Sevlievo</city>
        <zip>05400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Ii Sofia Eood</name>
      <address>
        <city>Sofia</city>
        <zip>01000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital For Active Treatment Aleksandrovska</name>
      <address>
        <city>Sofia</city>
        <zip>01431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center Xxviii - Sofia - Eood</name>
      <address>
        <city>Sofia</city>
        <zip>01592</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Eurohealth</name>
      <address>
        <city>Sofia</city>
        <zip>01606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Simcoderm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Centre For Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xlr8 Medical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research Corporation</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Le Bateau Blanc</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Archet 2 Derm Dept</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux - Hospital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse Hopital Larrey Centre de Reference Des Maladies Rares de La Peau Service de Dermatol</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Mahlow</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Munster Dermatologie</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus - Polska Sp Z Oo Oddzial W Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial W Gdyni</name>
      <address>
        <city>Gdynia</city>
        <zip>81-537</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus - Sp Z Oo Oddzial W Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Affiliate - Krakowskie Centrum Medyczne</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp Z Oo Oddzial W Lodzi</name>
      <address>
        <city>Lodz</city>
        <zip>90-127</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp Z Oo Oddzial W Czestochowie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermedic Dr. Zdybski</name>
      <address>
        <city>OSTROWIEC Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial W Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lubeskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poradnia Dermatologiczno-Wenerologiczna Mediderm S.C. Nzoz</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial Warszawie</name>
      <address>
        <city>Warsaw</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>High-Med Przychodnia Specjalistycza</name>
      <address>
        <city>Warsaw</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. Z O.O. Oddzial We Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermmedica Sp. Z O.O.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ico Hospital Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermomedic</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra (Cun)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INCB018424</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

